Skip to content

Clinical Evaluation of CARESTREAM Vue PACS v12.2 MR Perfusion and Diffusion

Clinical Evaluation of CARESTREAM Vue PACS v12.2 MR Perfusion and Diffusion

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03030872
Enrollment
68
Registered
2017-01-25
Start date
2017-01-07
Completion date
2017-01-12
Last updated
2018-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemia

Brief summary

The objective of this study is to compare the diagnostic value of MR DSC-Perfusion (Perfusion Module), MR DWI (Diffusion Module) and MR DTI (Diffusion Module) in CARESTREAM Vue PACS (investigational device) to the Olea Sphere PACS with Perfusion and DWI Modules (predicate device). Therefore, there will be several separate objectives depending on the type of acquisition:

Detailed description

Carestream Health, Inc. will investigate the imaging performance of the CARESTREAM Vue PACS v12.2 Magnetic Resonance (MR) Perfusion and Diffusion Weighted Imaging (investigational device) performance. Evaluation of MR Dynamic Susceptibility Contrast-Enhanced Perfusion Weighted Imaging (DSC-Perfusion), MR Diffusion Weighted Imaging (DWI) and MR Diffusion Tensor Imaging (DTI) was compared to the predicate device, the Olea Sphere PACS with Perfusion and DWI Modules. MR DSC-Perfusion of the brain is a method for evaluating blood flow in the brain and producing optimized parametric maps that help visualize this blood flow. MR DWI is a method to evaluate the motion of water molecules within bodily tissues. MR DTI is an extension of DWI that allows extraction of the diffusion tensor. The purpose of this study is to demonstrate equivalent clinical quality between the investigational and predicate devices using a radiologist evaluation of key metrics which are applicable to MR DSC-Perfusion, MR DWI, and MR DTI images.

Interventions

The study evaluated retrospective de-identified cases that were processed after the imaging procedure had been completed (off-line) using a dedicated workstation.

Sponsors

Carestream Health, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Retrospective patient MR DSC-Perfusion cases with subject/patient 18 years of age or older. * Retrospective patient MR DWI with subject/patient 18 years of age or older. * Retrospective patient MR DTI cases with subject/patient 18 years of age or older. * Informed consent is not required if waiver of consent is approved by the hospital IRB/Ethics Committee

Exclusion criteria

* Low quality images, or images that are not clinically acceptable for clinical diagnostic reading as determined by the Principal Investigator * Subject less than 18 years of age

Design outcomes

Primary

MeasureTime frameDescription
Diagnostic value comparison of Carestream Vue PACS v12.2 MR Perfusion and Diffusion (investigational software) images to the Olea Shere PACS with Perfusion and DWI Modules (predicate software) images.January 2017Diagnostic value of investigational images compared to the diagnostic value of predicate images as assessed by a radiologist evaluation of key metrics.

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026